Building a Tool to Predict Dementia After a Stroke
Combines genetic, brain scan and memory data from stroke survivors and healthy people.
Plain-language title generated from the registry record
Registry title: Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia
Key facts
- Where
- Gyeonggi-do, South KoreaSee the site
Where in South Korea
- Bundang CHA Medical CenterGyeonggi-do, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seyoung Shin
- Trial code
- NCT07660263
- Record updated
- 29 July 2026
- Original description
To collect large-scale multimodal data, including genomic information, neuroimaging, neurophysiological measures, cognitive assessments, and clinical characteristics from stroke survivors and healthy controls.Read full original descriptionShow less
Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia: An Ambidirectional Patient-Control Cohort Study
To collect large-scale multimodal data, including genomic information, neuroimaging, neurophysiological measures, cognitive assessments, and clinical characteristics from stroke survivors and healthy controls.
This study aims to develop and validate an integrated prediction model for identifying individuals at high risk of post-stroke vascular dementia and to establish a foundation for precision medicine approaches in stroke-related cognitive impairment.
Inclusion: Healthy Control Group:; Adults aged 19 years or older; Able to be age- and sex-matched to the stroke cohort; No history of stroke, transient ischemic attack (TIA), or other central nervous system disorders; Cognitive function within the normal range for age and education level based on screening assessments (K-MMSE and K-MoCA); Able to understand the study procedures and provide written informed consent; Stroke Patient Group:; Adults aged 19 years or older; First-ever ischemic or hemorrhagic stroke confirmed by CT or MRI; Enrolled in one of the following strata according to time since stroke onset:; Stratum A: 7 days to 3 months after stroke onset. Stratum B: >3 months to 12 months after stroke onset. Stratum C: >12 months to 36 months after stroke onset; Able to understand the study procedures and provide written informed consent, or consent provided by a legally authorized representative when applicable.
Exclusion: Stroke Patient Group:; Impaired ability to provide consent (MMSE <10) without an accompanying caregiver or legally authorized representative; History of dementia due to causes other than stroke (e.g., Alzheimer's disease) prior to stroke onset; History of major neurological disorders affecting cognition prior to stroke onset (e.g., Parkinson's disease, brain tumor, multiple sclerosis); Severe aphasia or impaired consciousness preventing completion of cognitive assessments; Current or pre-stroke severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications; Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL); Contraindication to MRI (e.g., metallic implants) or refusal to provide blood samples for genomic analysis; Any condition that, in the opinion of the investigator, would make participation unsuitable; Healthy Control Group:; Current severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications; Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL); Severe medical illness considered inappropriate for study participation; Any condition that, in the opinion of the investigator, would make participation unsuitable.